The $150 Billion Market Built on Your BMI

Good morning, and welcome to your daily HigherIQ briefing. It's Thursday, February 5th. In 1832, a Belgian mathematician named Adolphe Quetelet was trying to describe the "average man." Not diagnose anyone. Not prescribe treatment. Just find a statistical shortcut for comparing body sizes across populations. He divided weight by height squared, called it an index, and moved on. Nearly two hundred years later, that formula is the single metric that determines whether you're obese, whether your insurance covers a weight loss drug, and whether you're counted in the billion-person global obesity epidemic that has spawned the most valuable pharmaceutical market of the century. This week, that market cracked wide open. The company that started the weight loss drug revolution just lost more value than most countries produce in a year. And the deeper you look, the more the crack runs all the way down to the foundation.

Today we're asking a question that a hundred and fifty billion dollars is riding on: what if the biggest drug market in history is built on a number that doesn't actually measure health?

Two years ago, Novo Nordisk was Europe's most valuable company. Market cap above six hundred billion dollars, larger than the entire GDP of Denmark. The company had spent a century making insulin, but its breakthrough was semaglutide, the molecule behind Ozempic and Wegovy, drugs that helped patients lose around fifteen percent of their body weight. Demand outstripped supply. Wall Street projected a hundred-and-fifty-billion-dollar obesity drug market. Novo owned the pole position. Then on Tuesday, Novo told investors its sales would decline this year by as much as thirteen percent. Not slow down. Decline. The stock, which was down nearly 40 percent in 2025, tumbled again. Four hundred billion in market value, gone in under two years. CEO Mike Doustdar called it "unprecedented pricing pressure." Then, almost comically, within twenty-four hours, rival Eli Lilly reported earnings that crushed every estimate. Revenue up more than forty percent. Its obesity drug Zepbound posted over four billion in quarterly U.S. sales, more than doubling year over year. Lilly guided for north of eighty billion in 2026 revenue, about twenty-five percent growth. Same market. Same government pricing pressure. Same Trump deal forcing lower prices. Opposite trajectories. If you owned both stocks equally two years ago, you'd have watched one double and the other get cut in half.

The HigherIQ take: three forces are hitting Novo at once. Trump's Most Favored Nations agreement is forcing steep Medicare discounts, with deeper cuts coming in 2027. Semaglutide patents are expiring across international markets where Novo was seeing massive volume growth. And Lilly's drug tirzepatide simply works better, producing around twenty percent weight loss in trials versus Novo's fifteen. On top of that, over a million Americans are already using cheaper compounded semaglutide knockoffs from compounding pharmacies, cutting into the branded market from below. Lilly now controls about sixty percent of U.S. GLP-1 prescriptions. Two years ago, Novo held the lead. But this isn't just a story about one company losing its edge. It's about what happens when the foundation beneath the entire market starts showing cracks.

Quetelet never intended his formula to diagnose individuals. It wasn't even called "body mass index" until 1972, when a researcher named Ancel Keys needed a quick proxy for body fat in heart disease studies. Keys himself admitted it was imperfect, but it had one thing going for it: simplicity. No lab work, no scans, no nuance. That simplicity is why BMI became the backbone of the obesity industry. The WHO adopted it. Insurance companies built coverage criteria around it. Every major weight loss drug trial uses BMI thresholds for eligibility. A BMI of thirty qualifies you as obese. Below that, you're generally out of luck regardless of your actual metabolic health. To put the absurdity in perspective, by BMI standards, most NFL running backs are clinically obese. A five-foot-ten athlete at two hundred pounds with visible abs would qualify.

The problem is that BMI can't distinguish muscle from fat. It can't tell a powerlifter from a couch potato if they weigh the same. It doesn't know where your fat sits, which matters enormously, because visceral fat around your organs is far more dangerous than subcutaneous fat under your skin. Research shows that as many as one in three people BMI classifies as obese have perfectly normal metabolic profiles: healthy blood pressure, blood sugar, cholesterol, inflammation. Meanwhile, a meaningful share of "normal weight" people have terrible metabolic health and elevated cardiovascular risk.

Better metrics exist. Waist-to-height ratio predicts heart disease and diabetes more accurately, and it takes ten seconds with a tape measure. But it hasn't replaced BMI in clinical guidelines or insurance decisions. The entire commercial ecosystem of GLP-1 drugs is built on a formula sketched in 1832 to describe averages. Here's the HigherIQ math. If even twenty percent of people BMI labels as obese are metabolically healthy, the "addressable market" powering Wall Street's projections includes tens of millions who may not need pharmaceutical treatment. And if a meaningful share of normal-weight people have hidden metabolic dysfunction, tens of millions more need help but aren't being counted. The market isn't just the wrong size. It might be aimed at the wrong people.

Now layer on what happens after patients start the drugs. Tens of millions of people are now on GLP-1s worldwide, extraordinary for a drug class that barely existed five years ago. But roughly half of patients quit within the first year. The reasons are a cocktail of nausea that never fully goes away for some, costs that insurance often won't cover, and the dawning realization that this isn't a course of treatment with an end date. It's a subscription. When patients stop, about two-thirds of the weight comes back within a year.

That's a market model with a leaky bucket. The drugs work brilliantly while you're on them, but if half your patients quit and most regain the weight, recurring revenue is far less recurring than the models assumed, and public health impact is smaller than prescription volumes suggest. And here's what makes the regain problem worse than it looks. When you lose weight on a GLP-1, up to forty percent of what you're losing isn't fat. It's lean body mass, which includes muscle. Losing muscle tanks your metabolic rate, meaning your body burns fewer calories at rest. So when you stop the drug and the appetite suppression disappears, the hunger comes roaring back, but now you're burning less fuel than before you started. You regain the weight, except this time more of it is fat. Compositionally, you can end up worse off than where you began. Researchers say resistance training and high-protein diets meaningfully offset the muscle loss, but that requires lifestyle interventions most prescribers aren't emphasizing, and most patients aren't getting.

Novo's response is the Wegovy pill, launched in early January at under a hundred and fifty bucks a month, a fraction of the injectable's cost. Early results are strong. Fifty thousand weekly prescriptions within the first few weeks, and the vast majority going to patients who've never taken a GLP-1 before, meaning the pill is expanding the market, not cannibalizing injectables. Lilly has its own oral drug, orforglipron, expected this year. The real war will be fought with pills at price points that make long-term use realistic.

So here's where it all converges. The weight loss drug market is real. The drugs work. They're getting cheaper. More people will take them. But the metric that defines the market is a two-hundred-year-old shortcut that doesn't measure health. Half of patients quit within a year. And the weight they're losing isn't always the right weight to lose.

What we're watching with Novo and Lilly isn't just a pharmaceutical rivalry. It's the first stress test of whether we're building a system that treats obesity as a lifelong prescription, or one that uses these drugs as a bridge to the exercise, nutrition, and behavioral changes that actually fix what's broken underneath. Some forward-thinking providers are already moving in that direction, pairing GLP-1 prescriptions with structured resistance training programs, high-protein nutrition plans, and metabolic panels that measure what actually matters: blood sugar, inflammation, visceral fat. Not just a number on a scale. That's what a bridge looks like. The question is whether the system is built to support it, or whether it's easier to just keep refilling the prescription. Novo's crash suggests the subscription model is harder than anyone assumed. Lilly's surge suggests the better drug wins anyway. Both might be right. The hundred-and-fifty-billion-dollar question isn't whether people will take these drugs. It's whether we'll look back in twenty years and realize we spent decades optimizing for a number that a Belgian statistician sketched out in 1832, when the actual problem was metabolic health all along. Stay informed, stay curious, and the next time someone asks for your BMI, maybe ask them what, exactly, they think it's measuring. Have a great Thursday.